Table 2 Baseline demographics and disease characteristics
Demographics and disease characteristics | Analyzed patients (n = 495) | |
|---|---|---|
EBRT (n = 361) | BQT (n = 134) | |
Median age, years (range) | 73.0 (48.0–84.0) | 67.0 (48.0–82.0) |
Gleason score (grouped),a n (%) | ||
Grade group 1 Grade group 2 Grade group 3 Grade group 4 Grade group 5 | 97 (26.9) 94 (26.0) 74 (20.5) 55 (15.2) 41 (11.4) | 113 (84.3) 21 (15.7) 0 0 0 |
Median prostate-specific antigen at diagnosis, ng/mL (range) | 8.1 (1.7–342.0) | 5.9 (1.0–15.7) |
Median prostate-specific antigen at initial EBRT/BQT, ng/mL (range) | 3.5 (.0–100.0) | 5.8 (.8–17.2) |
Median testosterone at initial EBRT/BQT, ng/dL (range) | n = 177 10.0 (.0–913.0) | n = 21 291.0 (2.6–619.6) |
TNM stage at initial EBRT/BQT, n (%) | ||
T1c T2 T3 | 104 (28.8) 148 (41.0) 68 (18.8) | 91 (67.9) 19 (14.2) 0 |
Eastern Cooperative Oncology Group performance status at initial EBRT/BQT, n (%) | n = 341 | n = 130 |
0 1 2 Not available | 314 (92.1) 23 (6.7) 4 (1.2) 20 | 125 (96.2) 5 (3.8) 0 4 |
Type of BQT, n (%) | ||
Low-dose BQT/seed High-dose BQT | NA | 118 (88.1) 16 (11.9) |
Location of EBRT treatment, n (%) | ||
Prostate Lymph nodes Seminal vesicles | 361 (100) 94 (26.0) 280 (77.6) | NA |
Type of EBRT treatment,b n (%) | ||
3D CRT IMRT or VMAT | 104 (29.1) 254 (70.9) | NA |
Neo-adjuvant hormone treatment, n (%) | ||
Prior to EBRT/BQT Initiating EBRT/BQT | 224 (62.0) 219 (97.8) 5 (2.2) | 8 (6.0) 8 (100.0) – |
Previous interventions, n (%) | ||
Yes No Unknown | 141 (39.1) 213 (59.0) 7 (1.9) | 25 (18.7) 109 (81.3) |
Previous surgery, n (%) | ||
TURP | 39 (10.8) | 8 (6.0) |